



Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup

Pilar Garrido,¹ Nadia Chouaki,² Monika Serke,³ Philippe Giraud,⁴ Umberto Ricardi,⁵ Carmen Vallejo,⁶ Carla Visseren-Grul,⁷ Victoria Soldatenkova,⁸ Silvia Novello⁹

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/esmoopen-2016-000141>).

To cite: Garrido P, Chouaki N, Serke M, *et al.* Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup. *ESMO Open* 2017;**2**:e000141. doi:10.1136/esmoopen-2016-000141

Received 6 December 2016
Accepted 8 December 2016

For numbered affiliations see end of article.

Correspondence to
Dr Pilar Garrido; pilargarrido@gmail.com

Concurrent chemoradiotherapy (CT+RT) is a standard of care for good-performance patients with unresectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).^{1,2} In a phase II study, treatment with two cycles of pemetrexed-cisplatin (Pem-Cis) induction, followed by full-dose Pem-Cis plus concurrent RT was well tolerated and effective in 90 patients with stage IIIA/IIIB unresectable, non-squamous NSCLC.³ Here, we report by-age subgroup data for 17 elderly (aged >70 years) and 73 non-elderly patients (aged ≤70 years).

The Eastern Cooperative Oncology Group performance status 0–1, no prior systemic therapy, adequate pulmonary function (FEV1 >50% and carbon monoxide diffusing capacity (DLCO) >40% of predicted normal value) and a total lung volume to receive at least 20 Gy (V_{20}) of ≤35% were required (patient characteristics: see online supplementary material). Patients received two 3-week cycles of Pem 500 mg/m² and Cis 75 mg/m² as per PEM label (vitamin supplementation). Patients with complete response (CR), partial response or stable disease were then eligible for concurrent CT+RT, which included two additional cycles of full-dose Pem-Cis CT and RT (66 Gy, 33 fractions).

Of 17 elderly patients, 16 (94.1%) started concurrent CT+RT and 12 (70.6%) completed CT+RT as planned. Of 73 non-elderly patients, 59 (80.8%) started concurrent CT+RT and 52 (71.2%) completed CT+RT as planned.

The regimen was effective both in the elderly and non-elderly patient subgroups, with 1-year progression-free survival rates of 53.3% and 44.9% and median overall survival

times of 25.1 and 26.2 months, respectively (**figure 1**). Two elderly patients achieved CR. In one patient, the tumour became amenable to surgical resection after CT+RT, response was classified as CR after surgery, the other achieved CR after CT+RT alone. Overall response and disease control rates in this subgroup were 64.7% and 94.1%, respectively (non-elderly: 58.9% and 74.0%).

During concurrent CT+RT, 8 of the 16 elderly patients who started CT+RT (50.0%) had grade (G)3/4 treatment-emergent adverse events (TEAEs; non-elderly: 25 of 59, 42.4%; details in online supplementary material). No elderly patient died due to drug toxicity, none required transfusions. Neutropaenia and leucopenia were the most frequent haematologic toxicities, oesophagitis and dysphagia were the most common non-haematologic toxicities; 18.8% of the elderly patients had G3 oesophagitis, none had febrile neutropaenia or G3/4 radiation dermatitis/mucositis, G3/4 radiation pneumonitis, G3/4 dehydration or diarrhoea.

These data align with results from the overall study population,³ suggesting that this regimen is feasible in elderly and non-elderly patients alike and may help in making the disease surgically resectable in elderly patients with good performance. Findings should be interpreted with caution due to the exploratory nature and small number of elderly patients included. Nevertheless, to our knowledge, these are the first data for elderly patients receiving Pem-Cis induction followed by Pem-Cis and concurrent RT. The data suggest that fit elderly patients may tolerate concurrent CT+RT




Figure 1 Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. CI, confidence interval; m, median; N, number of all patients; n, number of patients with event; n.e., not estimable; OS, overall survival; PD, progressive disease; PFS, progression-free survival. Circles indicate censored patients.

and stand to gain survival benefits. The data provide a rationale for conducting more prospective studies in elderly patients with locally advanced NSCLC that may help to develop evidence-based recommendations

to improve management of these patients. Until more evidence is generated, performance status and comorbidities should predominate over age alone with respect to decision-making.⁴

**Author affiliations**¹Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain²Medical Oncology, Lilly France, Neuilly-sur-Seine, France³Thoracic Oncology Department, Hemer Lung Clinic, Hemer, Germany⁴Department of Oncology Radiotherapy, Georges Pompidou European Hospital, Paris, France⁵Department of Oncology, Radiation Oncology, University of Turin, Turin, Italy⁶Department of Oncology Radiotherapy, University Hospital Ramon y Cajal, Madrid, Spain⁷Medical–Oncology, Eli Lilly and Company, Houten, The Netherlands⁸Statistics, Oncology, Lilly Deutschland GmbH, Bad Homburg, Germany⁹Thoracic Oncology Unit, Department of Oncology, University of Turin, Turin, Italy**Acknowledgements** Trilogy Writing and Consulting GmbH, Frankfurt, Germany, provided medical writing support on behalf of Eli Lilly.**Funding** The study was funded by Eli Lilly and Company.**Competing interests** NC, CVG and VS are Eli Lilly and Company employees, and as such own some Lilly stock. PGa, MS and PGI have served as consultants for Eli Lilly. PGa and PGI have received speaker honoraria from Eli Lilly. PG and MS have received travel expenses from Eli Lilly. MS has received speaker honoraria from Eli Lilly, BMS, MSD, Boehringer, Roche, Hexal, Pfizer and AstraZeneca. SN has received speaker honoraria from Eli Lilly, AstraZeneca, MSD and Roche. UR and CV have no conflicts of interest to declare.**Provenance and peer review** Not commissioned; internally peer reviewed.**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Vansteenkiste J, De Ruyscher D, Eberhardt WE, *et al*; ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2013;24(Suppl 6):vi89–vi98.
2. Aupérin A, Le Péchoux C, Rolland E, *et al*. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol* 2010;28:2181–90.
3. Garrido P, Engel-Riedel W, Serke M, *et al*. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). *Lung Cancer* 2015;88:160–6.
4. Eberhardt WE, De Ruyscher D, Weder W, *et al*; Panel Members. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. *Ann Oncol* 2015;26:1573–88.



Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup

Pilar Garrido, Nadia Chouaki, Monika Serke, Philippe Giraud, Umberto Ricardi, Carmen Vallejo, Carla Visseren-Grul, Victoria Soldatenkova and Silvia Novello

ESMO Open 2017 2:

doi: [10.1136/esmoopen-2016-000141](https://doi.org/10.1136/esmoopen-2016-000141)

Updated information and services can be found at:
<http://esmoopen.bmj.com/content/2/1/e000141>

These include:

References

This article cites 4 articles, 3 of which you can access for free at:
<http://esmoopen.bmj.com/content/2/1/e000141#BIBL>

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>